We introduce new forecasts for FY 2017 and look at the key questions currently being asked of the company, namely the growth of vitamin D, the impact of losing a key royalty stream, the timing of the introduction of its troponin antibody and the impact that this will have on dividend payout. We conclude that the shares offer good long-term value, and we retain a nearterm 1250p target price, which implies 21% upside to the current price.
